Ablynx NV said that its antibody-fragment therapeutic, ALX-0061, has met the efficacy endpoint at week 12 in a Phase 1/2 trial of patients with rheumatoid arthritis. The compound targets the interleukin-6 receptor. ---Subscribe to MedNous to access this article--- Clinical Research Company News
